Skip to main content
Premium Trial:

Request an Annual Quote

Nanomix Nabs CE Mark for Point-of-Care COVID-19 Antigen Test

NEW YORK ─ Nanomix said on Friday that it has received the CE mark for its eLab COVID-19 antigen test which provides qualitative results in 15 minutes from an anterior nasal swab.

The test's nasal swab samples are transferred by a collection tube to a single-use, microfluidic cartridge, which detects the SARS-CoV-2 nucleocapsid antigen using the Nanomix eLab Analyzer. The test results can be printed, transmitted by Bluetooth, or shown as a quick response (QR) code.

"This assay complements our S1 Critical Infection Panel which provides valuable insight to clinicians as they diagnose and monitor severe coinfections including [for] COVID-19 patients," Nanomix Chief Commercial Officer John Hardesky said in a statement.

The Emeryville, California-based company noted it developed the antigen test with funding from the US Department of Health and Human Services' Biomedical Advanced Research and Development Authority.

In April 2020, Nanomix announced it had obtained up to about $570,000 in BARDA funding to support the development of COVID-19 point-of-care assays for its eLab analyzer.